IQWiG: First health economic evaluation completed

October 30, 2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results. In relation to their benefit, some drugs are markedly more expensive than others. The self-government of the German health care system can now be provided with well-founded information on the appropriate price at which the statutory health insurance (SHI) funds could reimburse a drug. It is now the responsibility of politicians to discuss and determine the future relevance of such evaluations in the health care system.

Complete health economic evaluation not possible for all drugs due to lack of data

In the present health economic evaluation IQWiG was commissioned by the Federal Joint Committee (G-BA) to determine the cost-effectiveness ratio of venlafaxine, duloxetine, bupropion, and mirtazapine compared to other currently available drugs and to placebo. For this purpose, the efficiency frontier method, which was adapted by IQWiG and an international expert panel, was applied. With this method, a price or price corridor can be determined within which a drug can be regarded as "cost-effective".

However, due to missing data it was not possible to present the results on an efficiency frontier for all drugs and all patient-relevant outcomes (e.g. quality of life) and derive prices adjusted for added benefit.

Prices markedly higher than appropriate

IQWiG was able to calculate such "added-benefit-adjusted reimbursement prices" for the outcomes "response" (to treatment), defined as a reduction in depressive symptoms of at least 50% on a disease-specific scale, and "remission". The latter is achieved if symptoms can be alleviated to an extent that the criteria for depression are no longer fulfilled.

The relation between their benefit for patients and the price reimbursed by the SHI funds shows marked differences between drugs; this applies to both outcomes. For each of the 4 drugs assessed, the current reimbursement price is higher than the "appropriate" price inferred from the respective efficiency frontier. However, 2 of the drugs assessed (mirtazapine and venlafaxine) have since been classified into a reference price group, meaning that the current price of each drug will probably have shifted closer to the efficiency frontier.

Legal situation has changed

The results of this health economic evaluation are not directly relevant to decision making, neither for drug prices nor for general reimbursement. This is due to a change in the legal situation since the report was commissioned. Originally, the results were supposed to form the basis of the decision on the setting of a "maximum reimbursable price" for drugs. This was the responsibility of the SHI umbrella organization ("GKV-Spitzenverband").

Since the introduction of the Act on the Reform of the Market for Medicinal Products (AMNOG), a health economic evaluation is primarily planned for the case where price negotiations fail after the regular early benefit assessment and where the arbitral verdict is also challenged. In this case the drug manufacturers or the SHI umbrella organization can apply for a health economic evaluation.

Successful test run

Despite the change in the legal situation, it was important for the Institute to complete the report. As the Institute's Director Jürgen Windeler explains: "We wanted to test whether the efficiency frontier method, which is the method preferred by IQWIG, is suitable and leads to robust results. And this test was successful. The report shows drug manufacturers and SHI funds what they can expect from a health economic evaluation and what not."

Challenges remain

IQWiG was also able to gain important experiences in this test run and identify open questions. For instance, it is still debatable how different aspects of benefit and harm, e.g. side effects, should be weighted and aggregated to an overall conclusion. One option is to use patient preferences. IQWiG has therefore tested methods on how to determine such preferences.

In addition, a lack of data was noticeable; on the cost side this applies, among other things, to SHI claims data, which are not freely available in Germany.

But gaps were also evident on the benefit side: on average, studies investigating the benefit of antidepressants lasted only 8 weeks. This time horizon, however, neither sufficiently reflects the treatment situation of patients affected by major depression, nor informs the self-government, as its decisions cannot be based on such a short period.

Important component for decisions in the health care system

Jürgen Windeler is certain that "the results of the health economic evaluation can nevertheless represent an important component in price negotiations and decisions on reimbursement. But we now need a discussion on the relevance of this component for decisions in the health care system. This will also represent a challenge for the new Minister of Health. The discussion also has to address the amount of resources that should be invested. This investment may be considerable, at least as long as cost data are not standardized. However, thanks to the experiences we have gained in the meantime, further health economic evaluations will probably be performed much faster."
-end-
Process of report production

IQWiG published the preliminary results in the form of the preliminary report in November 2012 and interested parties were invited to submit comments. Following a request from drug manufacturers, IQWiG prolonged the scheduled deadline by 4 weeks, which had never happened before in the Institute's assessments. At the end of the commenting procedure the preliminary report was revised and sent as a final report to the commissioning agency, the Federal Joint Committee (G-BA), in September 2013. The submitted written comments were published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.

The English-language executive summary provides an overview of the background, procedures and further results of the report.

Institute for Quality and Efficiency in Health Care

Related Health Care Articles from Brightsurf:

Study evaluates new World Health Organization Labor Care Guide for maternity care providers
The World Health Organization developed the new Labor Care Guide to support clinicians in providing good quality, women-centered care during labor and childbirth.

Six ways primary care "medical homes" are lowering health care spending
New analysis of 394 U.S. primary care practices identifies the aspects of care delivery that are associated with lower health care spending and lower utilization of emergency care and hospital admissions.

Modifiable health risks linked to more than $730 billion in US health care costs
Modifiable health risks, such as obesity, high blood pressure, and smoking, were linked to over $730 billion in health care spending in the US in 2016, according to a study published in The Lancet Public Health.

Spending on primary care vs. other US health care expenditures
National health care survey data were used to assess the amount of money spent on primary care relative to other areas of health care spending in the US from 2002 to 2016.

MU Health Care neurologist publishes guidance related to COVID-19 and stroke care
A University of Missouri Health Care neurologist has published more than 40 new recommendations for evaluating and treating stroke patients based on international research examining the link between stroke and novel coronavirus (COVID-19).

Large federal program aimed at providing better health care underfunds primary care
Despite a mandate to help patients make better-informed health care decisions, a ten-year research program established under the Affordable Care Act has funded a relatively small number of studies that examine primary care, the setting where the majority of patients in the US receive treatment.

International medical graduates care for Medicare patients with greater health care needs
A study by a Massachusetts General Hospital research team indicates that internal medicine physicians who are graduates of medical schools outside the US care for Medicare patients with more complex medical needs than those cared for by graduates of American medical schools.

The Lancet Global Health: Improved access to care not sufficient to improve health, as epidemic of poor quality care revealed
Of the 8.6 million deaths from conditions treatable by health care, poor-quality care is responsible for an estimated 5 million deaths per year -- more than deaths due to insufficient access to care (3.6 million) .

Under Affordable Care Act, Americans have had more preventive care for heart health
By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health.

High-deductible health care plans curb both cost and usage, including preventive care
A team of researchers based at IUPUI has conducted the first systematic review of studies examining the relationship between high-deductible health care plans and the use of health care services.

Read More: Health Care News and Health Care Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.